Macrogenics (MGNX) Non-Current Assets (2012 - 2026)
Macrogenics (MGNX) reported Non-Current Assets of $35.4 million for Q1 2026, down 16.78% year-over-year from $42.5 million in Q1 2025, and down 4.21% quarter-over-quarter from $36.9 million in Q4 2025.
Macrogenics (MGNX) Non-Current Assets (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 15 years of Non-Current Assets data on file, last reported at $35.4 million in Q1 2026.
- Non-Current Assets for Q1 2026 came in at $35.4 million, down 16.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $151.4 million (down 12.55% YoY), and the FY2025 annual result was $36.9 million, down 16.44% from the prior year.
- Non-Current Assets retreated to $35.4 million in Q1 2026 per MGNX's latest filing, from $36.9 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $58.3 million in Q4 2022 and troughed at $35.4 million in Q1 2026.
- A 5-year average of $45.9 million and a median of $45.7 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets advanced 4.67% in 2022, then fell 19.23% in 2023.
- A 5-year view of Non-Current Assets shows it stood at $58.3 million in 2022, then slipped by 19.23% to $47.1 million in 2023, then retreated by 6.19% to $44.2 million in 2024, then decreased by 16.44% to $36.9 million in 2025, then decreased by 4.21% to $35.4 million in 2026.
- Business Quant data shows MGNX's Non-Current Assets at $35.4 million in Q1 2026, $36.9 million in Q4 2025, and $38.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - | 35.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.35 Mn |
| Dec 31, 2025 | 36.91 Mn |
| Sep 30, 2025 | 38.67 Mn |
| Jun 30, 2025 | 40.47 Mn |
| Mar 31, 2025 | 42.48 Mn |
| Dec 31, 2024 | 44.17 Mn |
| Sep 30, 2024 | 42.30 Mn |
| Jun 30, 2024 | 44.19 Mn |
| Mar 31, 2024 | 45.71 Mn |
| Dec 31, 2023 | 47.08 Mn |
| Sep 30, 2023 | 48.65 Mn |
| Jun 30, 2023 | 50.98 Mn |
| Mar 31, 2023 | 54.56 Mn |
| Dec 31, 2022 | 58.29 Mn |
| Sep 30, 2022 | 47.54 Mn |
| Jun 30, 2022 | 50.41 Mn |
| Mar 31, 2022 | 53.24 Mn |
| Dec 31, 2021 | 55.69 Mn |
| Sep 30, 2021 | 57.46 Mn |
| Jun 30, 2021 | 58.92 Mn |